Jeschke MG, Barrow RE, Herndon DN
Chronic administration of GLP1 decreased body weight, fat mass, and food intake, whereas no glucoregulatory or insulin-sensitizing actions were detected (Fig
Use sterile solvents and syringes, disinfect vial stoppers, work in a clean environment, and minimize handling of open containers to reduce contamination risks
Only people who were deficient see a metabolic lift
Abdominal symptoms such as distention, pain, and discomfort varied across agents
The choice of alternative therapy should be individualised based on glycaemic control requirements, cardiovascular risk profile, renal function, patient preferences, and other clinical factors, in accordance with NICE guidance (NG28: Type 2 diabetes in adults: management)